161 related articles for article (PubMed ID: 10206087)
1. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.
Ericsson H; Fakt C; Höglund L; Jolin-Mellgård A; Nordlander M; Sunzel M; Regårdh CG
Eur J Clin Pharmacol; 1999 Mar; 55(1):61-7. PubMed ID: 10206087
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson H; Fakt C; Jolin-Mellgård A; Nordlander M; Sohtell L; Sunzel M; Regårdh CG
Br J Clin Pharmacol; 1999 May; 47(5):531-8. PubMed ID: 10336577
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Ericsson H; Bredberg U; Eriksson U; Jolin-Mellgård A; Nordlander M; Regårdh CG
Anesthesiology; 2000 Apr; 92(4):993-1001. PubMed ID: 10754618
[TBL] [Abstract][Full Text] [Related]
4. Clevidipine: a review of its use in the management of acute hypertension.
Deeks ED; Keating GM; Keam SJ
Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
[TBL] [Abstract][Full Text] [Related]
5. Clevidipine in adult cardiac surgical patients: a dose-finding study.
Bailey JM; Lu W; Levy JH; Ramsay JG; Shore-Lesserson L; Prielipp RC; Brister NW; Roach GW; Jolin-Mellgard A; Nordlander M
Anesthesiology; 2002 May; 96(5):1086-94. PubMed ID: 11981147
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
Smith WB; Marbury TC; Komjathy SF; Sumeray MS; Williams GC; Hu MY; Mould DR
Eur J Clin Pharmacol; 2012 Oct; 68(10):1385-94. PubMed ID: 22457015
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
Ericsson H; Tholander B; Björkman JA; Nordlander M; Regårdh CG
Drug Metab Dispos; 1999 May; 27(5):558-64. PubMed ID: 10220482
[TBL] [Abstract][Full Text] [Related]
8. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.
Ericsson H; Schwieler J; Lindmark BO; Löfdahl P; Thulin T; Regårdh CG
Chirality; 2001; 13(3):130-4. PubMed ID: 11270321
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats.
Zhou Y; He XM; Li HQ; Ni Y; Xu MZ; Chen H; Li WY
J Huazhong Univ Sci Technolog Med Sci; 2014 Dec; 34(6):856-860. PubMed ID: 25480581
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass.
Vuylsteke A; Milner Q; Ericsson H; Mur D; Dunning J; Jolin-Mellgård A; Nordlander M; Latimer R
Br J Anaesth; 2000 Nov; 85(5):683-9. PubMed ID: 11094580
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Wang QD; Segawa D; Ericsson H; Sjöquist PO; Johansson L; Rydén L
J Cardiovasc Pharmacol; 2002 Aug; 40(2):228-34. PubMed ID: 12131552
[TBL] [Abstract][Full Text] [Related]
12. Clevidipine for controlled hypotension during spinal surgery in adolescents.
Tobias JD
Middle East J Anaesthesiol; 2011 Jun; 21(2):269-74. PubMed ID: 22435279
[TBL] [Abstract][Full Text] [Related]
13. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans.
Schwieler JH; Ericsson H; Löfdahl P; Thulin T; Kahan T
J Cardiovasc Pharmacol; 1999 Aug; 34(2):268-74. PubMed ID: 10445679
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Nordlander M; Sjöquist PO; Ericsson H; Rydén L
Cardiovasc Drug Rev; 2004; 22(3):227-50. PubMed ID: 15492770
[TBL] [Abstract][Full Text] [Related]
15. Clevidipine: a new intravenous option for the management of acute hypertension.
Ndefo UA; Erowele GI; Ebiasah R; Green W
Am J Health Syst Pharm; 2010 Mar; 67(5):351-60. PubMed ID: 20172984
[TBL] [Abstract][Full Text] [Related]
16. Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.
Frank Peacock W; Varon J; Ebrahimi R; Dunbar L; Pollack CV
Blood Press Suppl; 2011 Apr; 1(Suppl 1):20-5. PubMed ID: 21091269
[TBL] [Abstract][Full Text] [Related]
17. Clevidipine for controlled hypotension during spinal surgery in adolescents.
Tobias JD; Hoernschemeyer DG
J Neurosurg Anesthesiol; 2011 Oct; 23(4):347-51. PubMed ID: 21623231
[TBL] [Abstract][Full Text] [Related]
18. Clevidipine for the treatment of severe hypertension in adults.
Nguyen HM; Ma K; Pham DQ
Clin Ther; 2010 Jan; 32(1):11-23. PubMed ID: 20171407
[TBL] [Abstract][Full Text] [Related]
19. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.
Kenyon KW
Ann Pharmacother; 2009 Jul; 43(7):1258-65. PubMed ID: 19584385
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.
Gradman AH; Vivas Y
Expert Opin Investig Drugs; 2007 Sep; 16(9):1449-57. PubMed ID: 17714030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
